These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27747531)

  • 41. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis.
    Korhonen R; Moilanen E
    Basic Clin Pharmacol Toxicol; 2010 Jan; 106(1):13-21. PubMed ID: 19686542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.
    Emery P; Mease PJ; Rubbert-Roth A; Curtis JR; Müller-Ladner U; Gaylis NB; Williams S; Reynard M; Tyrrell H
    Rheumatology (Oxford); 2011 Dec; 50(12):2223-32. PubMed ID: 21926153
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What is the role of rituximab in the treatment of rheumatoid arthritis?
    Atzeni F; Doria A; Turiel M; Sarzi-Puttini P
    Autoimmun Rev; 2007 Sep; 6(8):553-8. PubMed ID: 17854748
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rituximab after methotrexate failure in rheumatoid arthritis: evaluation of the SERENE trial.
    Khan A; Scott D
    Expert Opin Biol Ther; 2011 Nov; 11(11):1515-8. PubMed ID: 21806480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.
    Rehnberg M; Amu S; Tarkowski A; Bokarewa MI; Brisslert M
    Arthritis Res Ther; 2009; 11(4):R123. PubMed ID: 19686595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.
    Berger JR; Malik V; Lacey S; Brunetta P; Lehane PB
    J Neurovirol; 2018 Jun; 24(3):323-331. PubMed ID: 29508305
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients.
    Genovese MC; Breedveld FC; Emery P; Cohen S; Keystone E; Matteson EL; Baptiste Y; Chai A; Burke L; Reiss W; Sweetser M; Shaw TM
    Ann Rheum Dis; 2009 Dec; 68(12):1894-7. PubMed ID: 19155233
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis.
    Hsue PY; Scherzer R; Grunfeld C; Imboden J; Wu Y; Del Puerto G; Nitta E; Shigenaga J; Schnell Heringer A; Ganz P; Graf J
    J Am Heart Assoc; 2014 Oct; 3(5):e001267. PubMed ID: 25336464
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
    Yukawa N; Mimori T
    Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
    Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
    Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
    Breedveld F; Agarwal S; Yin M; Ren S; Li NF; Shaw TM; Davies BE
    J Clin Pharmacol; 2007 Sep; 47(9):1119-28. PubMed ID: 17766699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rituximab: new indication. In rheumatoid arthritis: for a few patients, with close monitoring.
    Prescrire Int; 2007 Oct; 16(91):186-8. PubMed ID: 17926823
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.
    Emery P; Gottenberg JE; Rubbert-Roth A; Sarzi-Puttini P; Choquette D; Taboada VM; Barile-Fabris L; Moots RJ; Ostor A; Andrianakos A; Gemmen E; Mpofu C; Chung C; Gylvin LH; Finckh A
    Ann Rheum Dis; 2015 Jun; 74(6):979-84. PubMed ID: 24442884
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment.
    Vital EM; Dass S; Rawstron AC; Buch MH; Goëb V; Henshaw K; Ponchel F; Emery P
    Arthritis Rheum; 2010 May; 62(5):1273-9. PubMed ID: 20131284
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Posterior reversible encephalopathy syndrome: A rare complication of rituximab therapy in rheumatoid arthritis.
    Hussain Awan M; Samreen S; Perveen S; Salim B; Gul H; Khan A
    Rheumatol Immunol Res; 2023 Jun; 4(2):98-101. PubMed ID: 37485477
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of tumor necrosis factor α in rheumatoid arthritis.
    Kulp W; Corzillus M; Greiner W; Pientka L; Siebert U; von der Schulenburg JM; Wasem J
    GMS Health Technol Assess; 2005 Dec; 1():Doc12. PubMed ID: 21289933
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
    Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry.
    Harrold LR; Reed GW; Magner R; Shewade A; John A; Greenberg JD; Kremer JM
    Arthritis Res Ther; 2015 Sep; 17(1):256. PubMed ID: 26382589
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial.
    Vital EM; Dass S; Buch MH; Rawstron AC; Emery P
    Ann Rheum Dis; 2015 Jun; 74(6):1195-201. PubMed ID: 24443001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.